Nanotechnology of Cancer Therapy: An Overview
Abstract
Nanotechnology is the study and use of structures between 1 nanometer and 100 nanometers in size. Nanotechnology is definitely a medical boon for diagnosis, treatment and prevention of cancer diseases. Nanoparticulate technology is of particular use in developing a new generation of more effective cancer therapies capable of overcoming many biological, biophysical and biomedical barriers that the body stages against a standard intervention. Nanoparticles that deliver chemotherapy drugs directly to cancer cells are under development. Nanomedicine application areas include drugdelivery, therapy, diagonistic, imaging and antimicrobial techniques. The formed nano particles can be used in wide range of therapeutic treatment of cancer. To overcome problems of systemic toxicity associated with chemotherapy and enhance treatment resolution of cancer therapies, nanotechnology is increasingly providing many novel approaches, especially to energy-based cancer therapies. Nonmaterial and biomarkers of cancer, general principle of drug targeting to cancer, intracellular mechanisms, and nanoparticles based formulation in market, several recent applications in medicine as diagnostic and therapeutic are discussed. This article aim to overview on all the parts of nanotechnology in cancer therapy
References
2.Ruoslahti E. Antiangiogenics meet nanotechnology, Cancer Cell 2002; 2: 97–98.
3.Derfus AM, Chan WC, Bhatia SN. Intracellular delivery of quantum dots for live cell labeling and organelle tracking, Advanced Materials. 2004; 16: 961–966.
4.Harisinghani MG and Weissleder R. Sensitive, noninvasive detection of lymph node metastases,Plos Medicine,2004;1: 202–209.
5.Majoros IJ, Thomas TP, Mehta CB and Baker JR. Poly(amidoamine) dendrimer-basedmultifunctional engineered nanodevice for cancer therapy, Journal of Medicinal Chemistry. 2005;48:5892–5899.
6.Sengupta S et al. Temporal targeting of tumour cells and neovasculature with a nanoscale deliverysystem, Nature,2005; 436:568–572.
7.Akerman ME Chan WC, Laakkonen P, Bhatia SN and Ruoslahti E. Nanocrystaltargeting in vivo, Proceedings of the National Academy of Sciences of the United States of America, 2002; 99: 12617–12621.
8.Thomas TP. et al. In vitro targeting of synthesized antibody-conjugated dendrimer nanoparticles, Biomacromolecules,2004;5: 2269–2274.
9.Gordon, AN et al., Recurrent epithelial ovarian carcinoma: A randomized phase III study of pegylatedliposomal doxorubicin versus topotecan, Journal of Clinical Oncology, 2001; 19: 3312–3322.
10.Shih MF, Wu CH, Cherng JY. Bioeffects of Transient and Low- Intensity Ultrasound on Nanoparticles for a Safe and Efficient DNA Delivery J Nanomedic Nanotechnol.2011;6:276.
11.www.lexinnova.com.
12.Elsaesser C, Howard V. Nano Systems Biology Group, Centre for Molecular Biosciences, University of Ulster, United Kingdom, toxicological of nanoparticles, Advanced Drug Delivery Reviews 64 (2012) 129–137
13.Agrahari V, Kabra V and Trivedi P. Development. Optimization and Characterization of Nanoparticle Drug Delivery System of Cisplatin.13th International Conference on Biomedical Engineering.2008; 23:1325-28.
14.Shah N, Chaudhari K, Dantuluri P, Murthy RSR, Das S. Paclitaxel-loaded PLGA nanoparticles surface modified with transferrin and Pluronic ((R)) P85, an in vitro cell line and in vivo biodistribution studies on rat model. J Drug Target. 2009; 17(7):533-42.
15.Roger W, Clive E. Cancer disease. In Roger Walker, The Textbook of Clinicalpharmacy and Therapeutics,Third Edition. New Delhi, Jaypee Brothers Medical Publishers (P) Ltd 2003; 265-353.
16.Peppa LB, Blanchette JO. Nanoparticle and targeted system for cancer therapy.Adv DrugDeliv Rev.2004;56:1649-59.
17.Lee RJ, Low PS. Folate-mediated tumor cell targeting of liposome-entrapped doxorubicin in vitro. BiochemBiophysActa 1995;1233: 134-144.
18.Kreuter J. Nanoparticles-a historical perspective. Int J Pharm.2007; 331:1-10.
19.Mohanraj VJ, Chen Y. Nanoparticles – A Review. Trop J Pharm Res. 2006; 5 (1):561-73.
20.Soppimath KS, Aminabhavi TM, KulkarniAR.Biodegradable polymeric nanoparticles asdrug delivery devices. J Control Release 2001; 70: 1 –20.
21.Gelperina S, Kisich K, Heifets L. The Potential Advantages of Nanoparticle Drug Delivery Systems in Chemotherapy of Tuberculosis. Am J RespirCrit Care Med. 2005; 172(12): 1487–1490.
22.Goforth R, Salem A, Zhu X, Miles S, Zhang X, Lee J and Sandler A. “Immune Stimulatory Antigen Loaded Particles Combined with Depletion of Regulatory T-Cells Induce Potent Tumor Specific Immunity in a Mouse Model of Melanoma,” Cancer Immunology Immunother-apy. 58; 4: 2009: 517-530.
23.Wang N and Wu X. “Synthesis, Characterization, Bio-degradation, and Drug Delivery Application of Biode-gradable Lactic/Glycolic Acid Oligomers: Part II. Bio-degradation and Drug Delivery Application,” Journal of Biomaterials Science, Polymer Edition 9, 1997: 75-87.
24.Nishikant CS, Keskar NJ, Argade PD. Nanoparticles: Advances in Drug Delivery SystemsResearch Journal of Pharmaceutical, Biological and Chemical Sciences. 2005; 21(5) : 975-985.
25.Muller RH, Bohm B etal. Nanosuspensions :A formulations approach for poorly soluble and poorly bioavailable drugs. In: DL Wise, Editor, Handbook of pharmaceutical released technology I stEdn,Marcel Dekker, New York, 2002: 345-357.
.